Previous 10 | Next 10 |
ALPHARETTA, Ga., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that two presen...
ALPHARETTA, Ga., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Management ...
Clearside Biomedical, Inc. (CLSD) Q3 2020 Earnings Conference Call November 11, 2020 04:30 PM ET Company Participants Jenny Kobin - Head, Investor Relations George Lasezkay - President & Chief Executive Officer Thomas Ciulla - Chief Medical Officer & Chief Development Officer Charles ...
Clearside Biomedical (CLSD): Q3 GAAP EPS of -$0.05 beats by $0.06.Revenue of $3.43M (+2350.0% Y/Y) beats by $1.91M.Cash and equivalents totaled $14.8M and will have sufficient resources to fund its planned operations into the Q3 2021.Press Release For further details see: Clearside...
- Initiation of Phase 1/2a Trial of CLS-AX ( axitinib injectable suspension ) for Wet Age-Related Macular Degeneration Expected by Year-End 2020 - - Phase 2 Trials Using SCS Microinjector ® Ongoing by Gene ...
ALPHARETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its third q...
Clearside Biomedical ([[CLSD]]) announced several clinical data presentations were given at the virtual 53rd Annual Scientific Meeting of The Retina Society. Also announced that data from the Company’s Phase 2 clinical trial in diabetic macular edema was published in Ophthalmology...
ALPHARETTA, Ga., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today several clinic...
Clearside Biomedical (NASDAQ: CLSD ) has announced that its licensing partner, Aura Biosciences, has dosed the first patient in its Phase 2 trial evaluating the safety and efficacy of suprachoroidal administration of AU-011 as a potential first-line treatment for patients with primary ch...
ALPHARETTA, Ga., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its licen...
News, Short Squeeze, Breakout and More Instantly...
Clearside Biomedical Inc. Company Name:
CLSD Stock Symbol:
NASDAQ Market:
Clearside Biomedical Inc. Website:
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), has opened registration for its virtual key opinion l...
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today the appointment of Glenn C. Yiu, M.D....
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ...